Wolverine blend vs KLOW blend
Written by Aaron CuhaReviewed Sep 2026
The short answer
Two seller blends for the same purpose, one with two parts and one with four. Neither mix has been studied in any species. The bigger blend is mostly one ingredient by weight, so the dosing math is the most useful thing to understand about it.
- Wolverine blend people
- 0
- Wolverine blend nulls
- 0
- KLOW blend people
- 13
- KLOW blend nulls
- 0
Dose
No human dose established
Amounts that circulate in forums and on vendor pages are not a human dose. No published study on this page has given this compound to people and reported a result.
Amounts for the BPC-157 in the blend, in mcg, commonly reported. The TB-500 moves with it in the label ratio.
Amounts commonly reported for the BPC-157 in this blend, recorded for this archive's reconstitution calculator, are 250, 500 and 750 mcg. They are self-reports rather than trial doses, and this archive does not recommend any of them. No human dose has been established for Wolverine blend.
| Reported amount | Where the number comes from |
|---|---|
| 250 mcg | Commonly reported, no published human dosing trial |
| 500 mcg | Commonly reported, no published human dosing trial |
| 750 mcg | Commonly reported, no published human dosing trial |
Dose
No human dose established
Amounts that circulate in forums and on vendor pages are not a human dose. Amounts that were given in studies sit in Human evidence on this page.
Amounts for the GHK-Cu in the blend, in mg, commonly reported. Every other component moves with it in the label ratio.
Amounts commonly reported for the GHK-Cu in this blend, recorded for this archive's reconstitution calculator, are 1, 2 and 3 mg. They are self-reports rather than trial doses, and this archive does not recommend any of them. No human dose has been established for KLOW blend.
| Reported amount | Where the number comes from |
|---|---|
| 1 mg | Commonly reported, no published human dosing trial |
| 2 mg | Commonly reported, no published human dosing trial |
| 3 mg | Commonly reported, no published human dosing trial |
First-hand reports are counted on each profile and never added together. This page sets two published records side by side. It does not pick a winner.
Column A
Wolverine blendWolverine (BPC-157 + TB-500)
Two gray-market healing peptides in one vial, usually 10 mg of each, sold for injury recovery. No study has ever tested the two together. A review of BPC-157 found 36 studies, and 35 of them were in animals or cells. And what shops sell as TB-500 is not thymosin beta 4. It is a seven amino acid piece of it.
Column B
KLOW blendKLOW (GHK-Cu + KPV + BPC-157 + TB-500)
KLOW is a seller's mix of four peptides in one vial, usually 50 mg GHK-Cu plus 10 mg each of KPV, BPC-157 and TB-500. It is sold for healing and inflammation. No study has tested the mix in any animal or person. GHK-Cu is 62.5% of the powder, so the vial holds about 7.9 mg of copper. Anyone dosing KLOW by units is mostly dosing a copper peptide.
Side by side, on the facts we can check
| What we compare | Wolverine blend | KLOW blend |
|---|---|---|
| Category | Healing & Recovery | Healing & Recovery |
| FDA status | Not approved, and the combination has never been reviewed. FDA staff looked at BPC-157 for the July 2026 meeting of the Pharmacy Compounding Advisory Committee, the panel that advises on what pharmacies may mix. They found no adequate human data, and they found wrongly labelled products on the market. Neither part is an approved medicine anywhere. | Not approved, and the combination has never been evaluated by any regulator. FDA staff evaluated BPC-157 for the July 2026 Pharmacy Compounding Advisory Committee and found no adequate human data along with mislabelled products in the market. |
| Half-life | Not defined for the blend, and the components differ. A systematic review reports BPC-157 as hepatically metabolised with a half-life under 30 minutes and renal clearance. | Not defined for the blend, and the components differ. No pharmacokinetic study of the mixture exists. |
| Molecular weight | A mixture. BPC-157 is about 1,419 Da. The Ac-LKKTETQ fragment identified in TB-500 is about 861 Da, well short of the roughly 4,960 Da of full-length thymosin beta 4. | A mixture. GHK-Cu is about 403 Da as the copper complex, KPV 342.4 Da, BPC-157 1,419.5 Da, and the Ac-LKKTETQ fragment sold as TB-500 about 889 Da. |
| How it works | People assume the effects add up, and assume is the key word. In animal and lab studies, BPC-157 is reported to raise growth hormone receptors and switch on pathways for cell growth and new blood vessels, while lowering inflammation signals. The full thymosin beta 4 protein grabs actin, a building block of the cell's frame, and helps cells move. The small piece actually in TB-500 sits inside the part of the protein that grabs actin. No paper describes what happens when the two are given together. Nobody knows if they add up, overlap or get in each other's way, or even if they stay stable mixed in one vial. | Assumed to be the four parts added together, and assumed is the key word. GHK-Cu carries copper into tissue. In lab dishes and in rat wound chambers, it drove the making of collagen and other skin building materials. KPV is the tail end of a skin hormone called alpha-MSH. In gut lining and immune cells in a dish, it blocks inflammation signals. BPC-157 and TB-500 work through the repair pathways on their own pages. No paper describes what these four do in the same syringe. Nobody knows if the effects add up, overlap or get in each other's way. And nobody knows if an acidic copper mix stays compatible with three other peptides over the weeks a vial sits in the fridge. |
| Studies in people | 1 | 2 |
| Evidence | Preliminary: 1 registered with no result | Limited: 1 completed trial, 13 people given it |
| Legal status, US | Not approved; research use only | Not approved; sold 'for research use only' |
Frequently asked questions
What is the difference between Wolverine blend and KLOW blend?
Wolverine blend: Two gray-market healing peptides in one vial, usually 10 mg of each, sold for injury recovery. No study has ever tested the two together. A review of BPC-157 found 36 studies, and 35 of them were in animals or cells. And what shops sell as TB-500 is not thymosin beta 4. It is a seven amino acid piece of it. KLOW blend: KLOW is a seller's mix of four peptides in one vial, usually 50 mg GHK-Cu plus 10 mg each of KPV, BPC-157 and TB-500. It is sold for healing and inflammation. No study has tested the mix in any animal or person. GHK-Cu is 62.5% of the powder, so the vial holds about 7.9 mg of copper. Anyone dosing KLOW by units is mostly dosing a copper peptide.
Which has stronger research evidence, Wolverine blend or KLOW blend?
Each compound gets a band worked out from facts we counted, with the math shown. Wolverine blend is Preliminary (1 registered with no result). KLOW blend is Limited (1 completed trial, 13 people given it). That counts how much has been done in people. It does not rate whether either one works, and neither one is called the winner.
Are Wolverine blend and KLOW blend FDA-approved?
Wolverine blend: Not approved, and the combination has never been reviewed. FDA staff looked at BPC-157 for the July 2026 meeting of the Pharmacy Compounding Advisory Committee, the panel that advises on what pharmacies may mix. They found no adequate human data, and they found wrongly labelled products on the market. Neither part is an approved medicine anywhere.. KLOW blend: Not approved, and the combination has never been evaluated by any regulator. FDA staff evaluated BPC-157 for the July 2026 Pharmacy Compounding Advisory Committee and found no adequate human data along with mislabelled products in the market..
Related posts
Blog articles that cover Wolverine blend or KLOW blend, newest first.
Reviewed Sep 2026. This page puts two published records side by side. It is for learning, and it is not medical advice. When this site shows a dose, it is the dose a trial or a clinic actually used, or what people say they did, with the source attached. None of it tells you what to take.